Anti-IL23α (Mirikizumab), Humanized Antibody

Datasheet
Specifications
Clonality: Monoclonal
Host: Recombinant
Reactivity: Human
Additional Information
Synonyms: LY-3074828, LY3074828, P19, SGRF, IL-23, IL23A, IL23P19
UniProt ID: DB14910

Immunogen

Human IL23α

Background

The research-grade biosimilar is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of IL-23 but does not bind to IL12. IL-23 is expressed and secreted by dendritic cells and macrophages. It belongs to the family of IL-12 cytokines and has two subunits: p40 that is shared with IL-12 and p19 that is unique for IL-23. IL-23 plays a critical role in maintaining and expanding Th17 cells. It also stimulates multiple innate immune cells such as myeloid cells and NK cells to produce proinflammatory cytokines that play an important role in the pathogenesis of inflammatory diseases such as Ulcerative Colitis (UC). By binding to the p19 subunit of IL-23, the antibody inhibits the release of proinflammatory cytokines and reduces the inflammatory response. The original drug is currently undergoing clinical trials to treat moderate-to-severe UC, psoriasis, and Crohn’s disease

  • Catalog Number
    A2174-100-BV
  • Supplier
    BioVision
  • Size
  • Shipping
    Blue Ice
  • Price
  • 555,00 €
Add to Cart
you need any help?

Please contact:

Dr. Monika Haas

Tel. +49 (0) 6221 71415 16 info@biocat.com